期刊文献+

液体闪烁计数器检测血浆肾素活性及醛固酮 被引量:2

Establishment of Fluid Scintillation Counter Method for Measurement of Plasma Renin Activity and Aldosterone
原文传递
导出
摘要 目的建立使用液体闪烁计数器检测血浆肾素活性(PRA)及醛固酮(ALD)的方法及临床应用。方法应用竞争机制原理,血浆(或标准品溶液)中的醛固酮(ALD)或血管紧张素I(AI)以及加入的放射性免疫试剂125I-ALD或125I-AI,竞争性地与一定量的特异性抗体产生免疫反应。血浆(或标准品溶液)中ALD或AI则优先与特异性抗体结合,剩余的抗体再与放射性免疫试剂125I-ALD或125I-AI结合。用驴抗兔免疫分离试剂沉淀被抗体结合的125I-ALD或125I-AI。离心,取上清液,使用β-液体闪烁计数器,检测未被抗体结合的游离的125I-ALD或125I-AI的放射性强度。建立相应的标准曲线方程,求得血浆中ALD或AI的含量,计算肾素活性(PRA)及ALD/PRA比值。结果变异系数RSD(%)为6.18%~10.79%,AI、ALD的回收率分别为87.61%~116.89%、82.98%~119.22%。结论本方法操作简便、准确度高、重复性好,可用于科研及临床。 Objective To establish a special fluid scintillation counter method for measuring plasma renin activity and aldo- sterone. Methods According to the principle of competition, aldosterone ( ALD ) or angiotensin I (AI) in plasma ( or the standard solution) bound with a certain amount of specific antibodies to compete with the Radioactive Immune Reagent 125I-ALD or 125I-AI to produce an immune reaction. The specific antibodies was given priority to combine with ALD or AI in plasma ( or the standard solution) ,the rest bound with the 125I-ALD or 125I-AI. The compound combined with the specific antibodies was precipitated by Donkey Anti-Rabbit antibody. After centrifuged, a certain amount of the supernatant was taken, the unbinding 125I-ALD or 125I-AI was detected by ^-fluid scintillation counter. To establish corresponding standard curves, the contents of ALD or AI in samples, the plasma renin activity and the ALD/PRA ratio were acquired according to the standard curves. Results Variation coefficient RSD ( % ) was 6.18% - 10.79% ,the recovery rates of AI and ALD were 87.61% - 116.89% and 82.98% - 119.22% ,re- spectively. Conclusion The method had more simplicities, high accuracy and reproducibility, and can be applied in the research and clinic.
出处 《中华全科医学》 2012年第12期1937-1939,共3页 Chinese Journal of General Practice
关键词 液体闪烁计数器 血管紧张素Ⅰ 肾素活性 醛固酮 Fluid scintillation counter Angiotensin I Activity of renin Aldosterone
  • 相关文献

参考文献11

  • 1严江涛,汪道文.原发性醛固酮增多症的诊疗进展[J].临床内科杂志,2005,22(7):433-435. 被引量:15
  • 2Brem AS, Morris DJ, Gong R. Aldosterone-induced fibrosis in the kid- ney : questions and controversies [ J ]. Am J Kidney Dis, 2011,58 ( 3 ) : 471-479.
  • 3Chen SY, Shen S J, Chou CW, et al. Primary aldosteronism caused by unilateral adrenal hyperplasia: rethinking the accuracy of imaging stud- ies[ J ]. J Chin Med Assoc ,2006,69 ( 3 ) : 125-129.
  • 4Gordon RD, Laragh JH, Funder JW, et al. Low renin hypertensive states : perspectives, unsolved problems, future research [ J ]. Trend En- docrinol Metab,2005,16(3) :108-113.
  • 5Fogari R, Preti P, Zoppi A, et al. Prevalence of primary aldosteronism among unselected hypertensive patients:a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test[ J]. Hypertens Res ,2007,30 ( 2 ) : 111-117.
  • 6Rios MC, Izquierdo A, Sotelo M, et al. Aldosterone/renin ratio in the diagnosis of primary aldosteronism [ J ]. Medicina ( B Aires), 2011,71 (6) :525-530.
  • 7Martinez-Aguayo A, Aglony M, Campino C, et al. Aldosterone, plasma Renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population [ J ]. Hypertension,2010,56 ( 3 ) : 391-396.
  • 8Maule S, Bertello C, Rabbia F, et al. Ventricular repolarization before and after treatment in patients with secondary hypertension due to re- nal-artery stenosis and primary aldosteronism [ J ]. Hypertens Res, 2011,34(10) :1078-1081.
  • 9Volpe M, Battistoni A, Chin D, et al. Renin as a biomarker of cardio- vascular disease in clinical practice [ J ]. Nutr Metab Cardiovasc Dis, 2012,22(4) :312-317.
  • 10曾正陪.应重视从高血压人群中鉴别原发性醛固酮增多症[J].中华内科杂志,2009,48(2):95-96. 被引量:10

二级参考文献29

  • 1周亚茹,曾正陪,张晶,童安莉,卢琳,宋爱羚,夏维波,付勇,姜艳,陈适,梁伟,茅江峰,张化冰,李伟.原发性醛固酮增多症的胰岛素抵抗及葡萄糖代谢异常[J].中华内分泌代谢杂志,2006,22(3):294-297. 被引量:27
  • 2梁伟,曾正陪,李汉忠,童安莉,卢琳,宋爱玲,姜艳,覃舒文,周亚茹,张晶,陈适.原发性醛固酮增多症患者术前术后胰岛B细胞功能变化的研究[J].中国实用内科杂志:临床前沿版,2006,26(11):1780-1783. 被引量:6
  • 3张晶,曾正陪,周亚茹,童安莉,卢琳,宋爱玲,阎朝丽,陈适,梁伟,李玉秀,覃舒文.原发性醛固酮增多症中低血钾对糖代谢的影响[J].中国医学科学院学报,2006,28(6):745-749. 被引量:6
  • 4Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2008,93:3266-3281.
  • 5Conn JW, Cohen EL, Rovner DR, et al. Normokalemic primary aldosteronism. A dectable cueable cause of curable " essential" hypertension. JAMA, 1965,193 : 200-206.
  • 6Fallo F, Federspil G, Veglio F, et al. The metabolic syndrome in primary aldosteronism. Curt Diab Rep,2008 ,8 :42-47.
  • 7Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab, 2006,91:454-459.
  • 8Chun TY, Pratt JH. Hyperaldosteronism: a commonly occurring underlying feature of essential hypertension and the metabolic syndrome? Curt Opin Endocrinol Diabetes Obes, 2007, 14 : 210- 212.
  • 9Phillips JL, Walther MM, Pez zullo JC, et al. Predictive Value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone - producing adrenal adenoma [ J ] . J Clin Endocrunol Metab,2000, 85 (12): 4526-4533.
  • 10Conn JW. Plasma rennin activity in primary aldsrteronism [ J ] . JAMA,1964, 90:222 -225.

共引文献25

同被引文献31

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部